Somatostatin Inhibitors
1 drugsAbout Somatostatin
Somatostatin, or somatotropin release-inhibiting factor (SRIF), is a cyclic peptide hormone regulating diverse physiological processes. It inhibits the release of other hormones and influences cell proliferation.
Somatostatin is a drug target due to its inhibitory effects. Currently, there is no genetic evidence data available linking Somatostatin to specific diseases.
One FDA-approved drug, Lanreotide Acetate, targets the Somatostatin pathway. It is a small molecule drug. Invagen Pharms is the only company with an approved drug.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Paraganglioma with only 1 trials.
Top Somatostatin Drugs
Invagen Pharms is the only company with an approved drug targeting Somatostatin.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity.
Somatostatin Drug Modality Landscape
Modalities
Routes of Administration
Somatostatin is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities to develop alternative modalities like antibodies or peptides to differentiate from existing therapies.
Somatostatin Clinical Trials 15 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 | 100% |
| Phase 2 | 5 | 2 | 2 | 1 | 50% |
| Phase 3 | 6 | 3 | 1 | 2 | 75% |
| Phase 4 | 2 | 1 | 1 | 0 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Somatostatin Drug Approval Timeline (1998 - 2024)
The first and most recent drug approval was Lanreotide Acetate in 2021.
Recent entry suggests renewed interest, but limited history indicates potential market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 19 clinical trials targeting Somatostatin.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities